



POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020, Phone: 011-26321889, Fax: 011-26321894
Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2015

₹ in lacs

Part I

Particulars	Quarter ended			Half Yearly Ended		Year Ended
	30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014	31.03.2015
	(Unaudited)			(Unaudited)		(Audited)
1 Income from operations						
a Net sales / income from operations	9,949.81	9,451.12	9,386.63	19,400.93	17,519.99	36,730.33
(net of excise duty)						
b Other operating income	96.56	79.07	177.37	175.63	322.96	638.50
Total income from operations (net)	10,046.37	9,530.19	9,564.00	19,576.56	17,842.95	37,368.83
2 Expenses						
a Cost of materials consumed	3,479.83	3,442.24	3,413.60	6,922.07	6,169.78	13,127.13
b Purchases of stock-in-trade	168.06	143.77	211.84	311.83	367.48	652.53
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	24.46	66.14	(349.04)	90.60	(322.19)	(306.83)
d Employee benefits expense	1,715.94	1,571.06	1,588.70	3,287.00	2,961.21	6,030.00
e Depreciation and amortisation expense	494.81	517.69	447.46	1,012.50	848.10	1,808.99
f Other expenses	2,589.46	2,505.69	2,331.77	5,095.15	4,372.17	9,602.68
Total expenses	8,472.56	8,246.59	7,644.33	16,719.15	14,396.55	30,914.50
3 Profit from operations before other income, finance costs and exceptional items (1-2)	1,573.81	1,283.60	1,919.67	2,857.41	3,446.40	6,454.33
4 Other income	299.08	171.17	75.21	470.25	124.88	822.14
5 Profit from ordinary activities before finance costs and exceptional items (3 + 4)	1,872.89	1,454.77	1,994.88	3,327.66	3,571.28	7,276.47
6 Finance costs	153.26	199.49	174.20	352.75	368.57	822.65
7 Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	1,719.63	1,255.28	1,820.68	2,974.91	3,202.71	6,453.82
8 Exceptional items	-	-	1,957.80	-	1,957.80	1,957.80
9 Profit from ordinary activities before tax (7 + 8)	1,719.63	1,255.28	3,778.48	2,974.91	5,160.51	8,411.62
10 Tax expense	458.42	279.90	1,051.21	738.32	1,462.40	2,309.90
11 Net Profit from ordinary activities after tax (9 - 10)	1,261.21	975.38	2,727.27	2,236.59	3,698.11	6,101.72
12 Extraordinary items	-	-	-	-	-	-
13 Net Profit for the period (11 + 12)	1,261.21	975.38	2,727.27	2,236.59	3,698.11	6,101.72
14 Paid-up equity share capital (Face Value of ₹ 5 each)	2,205.67	2,205.67	2,204.14	2,205.67	2,204.14	2,205.67
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	16,991.29
16 Earnings per share (before extraordinary items) (Yearly annualised, Qtr and half yearly not annualised) :						
Basic (₹)	2.86	2.21	6.19	5.07	8.39	13.83
Diluted (₹)	2.86	2.21	6.18	5.07	8.38	13.83

Part II - Select information for the Quarter ended September 30, 2015

A PARTICULARS OF SHAREHOLDING						
1 Public shareholding						
Number of shares	2,26,62,564	2,26,62,564	2,26,31,964	2,26,62,564	2,26,31,964	2,26,62,564
Percentage of shareholding	51.37%	51.37%	51.34%	51.37%	51.34%	51.37%
2 Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
Number of shares	-	-	-	-	-	-
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non - encumbered						
Number of shares	2,14,50,876	2,14,50,876	2,14,50,876	2,14,50,876	2,14,50,876	2,14,50,876
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
Percentage of shares (as a % of the total share capital of the company)	48.63%	48.63%	48.66%	48.63%	48.66%	48.63%
B Investor Complaints						
Pending at the beginning of the quarter	Nil					
Received during the quarter	Nil					
Disposed of during the quarter	Nil					
Remaining unresolved at the end of the quarter	Nil					




(Handwritten signature)

(Handwritten initials)

Particulars		₹ in lacs		Notes:	
		As at 30.09.2015 (Unaudited)	As at 31.03.2015 (Audited)		
A EQUITY AND LIABILITIES				1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 27th Oct 2015.	
1	Shareholders' funds				
	(a) Share capital	2,205.67	2,205.67		2. The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
	(b) Reserves and surplus	19,162.83	16,991.29		
	(b) Money Received Against Share Options	-	-	3. The statutory Auditors have carried out the limited review of the above results.	
	Sub-total - Shareholders' funds	21,368.50	19,196.96		
2	Non-current liabilities			4. The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.	
	(a) Long-term borrowings	3,270.55	4,024.56		
	(b) Deferred tax liabilities (net)	1,025.12	1,028.48		
	(c) Other long-term liabilities	359.94	280.90		
	(d) Long-term provisions	230.48	203.83		
	Sub-total - Non-current liabilities	4,886.09	5,537.77		
3	Current liabilities				
	(a) Short-term borrowings	1,448.27	1,807.37		
	(b) Trade payables	4,362.53	3,803.69		
	(c) Other current liabilities	5,599.09	3,741.55		
	(d) Short-term provisions	148.68	1,358.33		
	Sub-total - Current liabilities	11,558.57	10,710.94		
	TOTAL - EQUITY AND LIABILITIES	37,813.16	35,445.67		
B ASSETS					
1	Non-current assets				
	(a) Fixed assets	17,603.83	17,046.39		
	(b) Non-current investments	561.06	561.06		
	(c) Long-term loans and advances	1,963.04	2,361.81		
	(d) Other non-current assets	328.26	334.72		
	Sub-total - Non-current assets	20,456.19	20,303.98		
2	Current assets				
	(a) Inventories	5,018.28	5,387.30		
	(b) Trade receivables	8,356.64	5,949.14		
	(c) Cash and bank balances	2,181.52	1,983.38		
	(d) Short-term loans and advances	1,098.09	1,066.46		
	(e) Other current assets	702.44	755.41		
	Sub-total - Current assets	17,356.97	15,141.69		
	TOTAL - ASSETS	37,813.16	35,445.67		

By order of the Board


Himanshu Baid

Managing Director

Place : New Delhi

Date : 27.10.2015

DIN : 00014008



DOOGAR & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT

The Board of Directors


Poly Medicare Limited
232B, 3rd Floor, Okhla Industrial Estate,
Phase III, New Delhi – 110 020.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicare Limited (the 'Company') for the quarter ended September 30th, 2015 except for the disclosures regarding "Public Shareholding" and "Promoters and Promoters Group Shareholding" which have been traced from disclosures made by the Management and have not been audited by us. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 27/10/2015.

For Doogar & Associates
Chartered Accountants
Reg. No.000561N


(M. S. Agarwal)
Partner
M. No. 86580

